{"id":46891,"topic":"ai","source":"koreabiomed.com","title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","url_hash":"f627c4faef9a775276a4d63b3e89c335cc06669b","author":"","summary":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation koreabiomed.com","content":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI.\nThe company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).\nThe AX One-Stop Voucher program is designed to accelerate AI adoption among Korean companies by providing integrated support in the form of vouchers for AI solutions, cloud services, and data utilization based on participating companies' digital transformation plans.\nCHA Biotech will establish a consortium with Naver Cloud, Persona AI, and MediPlus to develop a generative AI-based software-as-a-service (SaaS) platform supporting the commercialization of cell therapies.\nUnder the partnership, Naver Cloud will provide high-performance cloud infrastructure, Persona AI will develop AI solutions and build the SaaS platform, and MediPlus will be responsible for data structuring and quality validation.\nThe consortium aims to reduce delays in processing documents and data generated throughout the entire cell therapy lifecycle, from research and development to manufacturing.\nA key focus of the project is applying AI to the preparation of chemistry, manufacturing, and controls (CMC) regulatory documentation, which is essential for demonstrating the quality consistency, safety, reproducibility, and clinical applicability of cell therapies.\nPreparing CMC documents requires integrating information from multiple departments, including manufacturing, quality assurance, clinical development, nonclinical research, and regulatory affairs. In addition to drafting and reviewing documents, considerable time and manpower are required to verify data consistency and identify errors or discrepancies across datasets.\nThrough the AI-powered platform, CHA Biotech plans to automate the drafting and review of CMC regulatory documents, improving document search, preparation, and review efficiency, enhancing regulatory compliance quality, strengthening global regulatory competitiveness, and shortening drug development and approval timelines.\nThe platform will also consolidate documents stored across multiple repositories and automate document preparation and review processes that have traditionally relied heavily on manual work.\nTo achieve this, the consortium will develop an integrated workflow covering search, analysis, content generation, and validation by leveraging a CMC-specialized large language model (LLM), four core validation agents -- including knowledge, template, and verification agents -- and AI operations (AIOps) technologies.\n\"We plan to build an automated system that structures dispersed document data and supports the entire regulatory documentation process, from drafting to validation,\" said Yoon Seok-hwan, executive director of CHA Biotech's AI team and principal investigator for the project. \"By demonstrating AI transformation in the highly demanding field of cell therapy CMC documentation, we aim to create a model case that accelerates AI adoption across the broader biotechnology industry.\"\nKim Young-gon, director of Persona AI's public business team, said, \"In high-precision domains such as CMC, agent-based AI combined with hyperautomation is essential because the process requires not only content generation but also rigorous validation. By integrating knowledge, template, and verification agents, we will enhance end-to-end automation for regulatory compliance and enable practical deployment in real-world operations.\"\nRelated articles\n- Matica Biotech, VaxDome partner to advance antiviral vaccine platform into clinic\n- CHA Biotech, Yonsei team up to support biohealth startups\n- CHA Biotech, Thermo Fisher Korea to build K-Bio CIC innovation hub in Pangyo\n- CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing\n- Matica Biolabs enters CAR-NK manufacturing with UCI Therapeutics CMO deal\n- CHA Biotech, Novartis Korea partner to launch K-Bio open innovation center\n- CHA Bio Group sells Solidus Investment stake to JW Holdings","image_url":"https://cdn.koreabiomed.com/news/thumbnail/202607/32553_35404_2219_v150.jpg","lang":"en","published_at":"2026-07-27T05:23:40+00:00","fetched_at":"2026-07-27T07:15:04+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).","cluster_id":null,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4164 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4164,"summary_length":365,"usable_text_length":4164,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4164,"summary_length":365}},"news_item":{"id":46891,"canonical_url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","source_url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","source_name":"koreabiomed.com","author":null,"published_at":"2026-07-27T05:23:40+00:00","locale":"en","topic":"ai","tags":[],"rss_summary":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation koreabiomed.com","full_text":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI.\nThe company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).\nThe AX One-Stop Voucher program is designed to accelerate AI adoption among Korean companies by providing integrated support in the form of vouchers for AI solutions, cloud services, and data utilization based on participating companies' digital transformation plans.\nCHA Biotech will establish a consortium with Naver Cloud, Persona AI, and MediPlus to develop a generative AI-based software-as-a-service (SaaS) platform supporting the commercialization of cell therapies.\nUnder the partnership, Naver Cloud will provide high-performance cloud infrastructure, Persona AI will develop AI solutions and build the SaaS platform, and MediPlus will be responsible for data structuring and quality validation.\nThe consortium aims to reduce delays in processing documents and data generated throughout the entire cell therapy lifecycle, from research and development to manufacturing.\nA key focus of the project is applying AI to the preparation of chemistry, manufacturing, and controls (CMC) regulatory documentation, which is essential for demonstrating the quality consistency, safety, reproducibility, and clinical applicability of cell therapies.\nPreparing CMC documents requires integrating information from multiple departments, including manufacturing, quality assurance, clinical development, nonclinical research, and regulatory affairs. In addition to drafting and reviewing documents, considerable time and manpower are required to verify data consistency and identify errors or discrepancies across datasets.\nThrough the AI-powered platform, CHA Biotech plans to automate the drafting and review of CMC regulatory documents, improving document search, preparation, and review efficiency, enhancing regulatory compliance quality, strengthening global regulatory competitiveness, and shortening drug development and approval timelines.\nThe platform will also consolidate documents stored across multiple repositories and automate document preparation and review processes that have traditionally relied heavily on manual work.\nTo achieve this, the consortium will develop an integrated workflow covering search, analysis, content generation, and validation by leveraging a CMC-specialized large language model (LLM), four core validation agents -- including knowledge, template, and verification agents -- and AI operations (AIOps) technologies.\n\"We plan to build an automated system that structures dispersed document data and supports the entire regulatory documentation process, from drafting to validation,\" said Yoon Seok-hwan, executive director of CHA Biotech's AI team and principal investigator for the project. \"By demonstrating AI transformation in the highly demanding field of cell therapy CMC documentation, we aim to create a model case that accelerates AI adoption across the broader biotechnology industry.\"\nKim Young-gon, director of Persona AI's public business team, said, \"In high-precision domains such as CMC, agent-based AI combined with hyperautomation is essential because the process requires not only content generation but also rigorous validation. By integrating knowledge, template, and verification agents, we will enhance end-to-end automation for regulatory compliance and enable practical deployment in real-world operations.\"\nRelated articles\n- Matica Biotech, VaxDome partner to advance antiviral vaccine platform into clinic\n- CHA Biotech, Yonsei team up to support biohealth startups\n- CHA Biotech, Thermo Fisher Korea to build K-Bio CIC innovation hub in Pangyo\n- CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing\n- Matica Biolabs enters CAR-NK manufacturing with UCI Therapeutics CMO deal\n- CHA Biotech, Novartis Korea partner to launch K-Bio open innovation center\n- CHA Bio Group sells Solidus Investment stake to JW Holdings","excerpt":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 4164 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4164 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4164,"summary_length":365,"usable_text_length":4164,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4164,"summary_length":365}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","summary":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).","source":"koreabiomed.com","date":"2026-07-27T05:23:40+00:00","content":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI.\nThe company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).\nThe AX One-Stop Voucher program is designed to accelerate AI adoption among Korean companies by providing integrated support in the form of vouchers for AI solutions, cloud services, and data utilization based on participating companies' digital transformation plans.\nCHA Biotech will establish a consortium with Naver Cloud, Persona AI, and MediPlus to develop a generative AI-based software-as-a-service (SaaS) platform supporting the commercialization of cell therapies.\nUnder the partnership, Naver Cloud will provide high-performance cloud infrastructure, Persona AI will develop AI solutions and build the SaaS platform, and MediPlus will be responsible for data structuring and quality validation.\nThe consortium aims to reduce delays in processing documents and data generated throughout the entire cell therapy lifecycle, from research and development to manufacturing.\nA key focus of the project is applying AI to the preparation of chemistry, manufacturing, and controls (CMC) regulatory documentation, which is essential for demonstrating the quality consistency, safety, reproducibility, and clinical applicability of cell therapies.\nPreparing CMC documents requires integrating information from multiple departments, including manufacturing, quality assurance, clinical development, nonclinical research, and regulatory affairs. In addition to drafting and reviewing documents, considerable time and manpower are required to verify data consistency and identify errors or discrepancies across datasets.\nThrough the AI-powered platform, CHA Biotech plans to automate the drafting and review of CMC regulatory documents, improving document search, preparation, and review efficiency, enhancing regulatory compliance quality, strengthening global regulatory competitiveness, and shortening drug development and approval timelines.\nThe platform will also consolidate documents stored across multiple repositories and automate document preparation and review processes that have traditionally relied heavily on manual work.\nTo achieve this, the consortium will develop an integrated workflow covering search, analysis, content generation, and validation by leveraging a CMC-specialized large language model (LLM), four core validation agents -- including knowledge, template, and verification agents -- and AI operations (AIOps) technologies.\n\"We plan to build an automated system that structures dispersed document data and supports the entire regulatory documentation process, from drafting to validation,\" said Yoon Seok-hwan, executive director of CHA Biotech's AI team and principal investigator for the project. \"By demonstrating AI transformation in the highly demanding field of cell therapy CMC documentation, we aim to create a model case that accelerates AI adoption across the broader biotechnology industry.\"\nKim Young-gon, director of Persona AI's public business team, said, \"In high-precision domains such as CMC, agent-based AI combined with hyperautomation is essential because the process requires not only content generation but also rigorous validation. By integrating knowledge, template, and verification agents, we will enhance end-to-end automation for regulatory compliance and enable practical deployment in real-world operations.\"\nRelated articles\n- Matica Biotech, VaxDome partner to advance antiviral vaccine platform into clinic\n- CHA Biotech, Yonsei team up to support biohealth startups\n- CHA Biotech, Thermo Fisher Korea to build K-Bio CIC innovation hub in Pangyo\n- CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing\n- Matica Biolabs enters CAR-NK manufacturing with UCI Therapeutics CMO deal\n- CHA Biotech, Novartis Korea partner to launch K-Bio open innovation center\n- CHA Bio Group sells Solidus Investment stake to JW Holdings","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 4164 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4164 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4164,"summary_length":365,"usable_text_length":4164,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4164,"summary_length":365}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/46891","export_markdown":"/api/items/46891/export?format=markdown","export_json":"/api/items/46891/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553"},"formats":{"full":{"id":46891,"title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","source":"koreabiomed.com","author":null,"published_at":"2026-07-27T05:23:40+00:00","locale":"en","topic":"ai","tags":[],"excerpt":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).","full_text":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI.\nThe company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).\nThe AX One-Stop Voucher program is designed to accelerate AI adoption among Korean companies by providing integrated support in the form of vouchers for AI solutions, cloud services, and data utilization based on participating companies' digital transformation plans.\nCHA Biotech will establish a consortium with Naver Cloud, Persona AI, and MediPlus to develop a generative AI-based software-as-a-service (SaaS) platform supporting the commercialization of cell therapies.\nUnder the partnership, Naver Cloud will provide high-performance cloud infrastructure, Persona AI will develop AI solutions and build the SaaS platform, and MediPlus will be responsible for data structuring and quality validation.\nThe consortium aims to reduce delays in processing documents and data generated throughout the entire cell therapy lifecycle, from research and development to manufacturing.\nA key focus of the project is applying AI to the preparation of chemistry, manufacturing, and controls (CMC) regulatory documentation, which is essential for demonstrating the quality consistency, safety, reproducibility, and clinical applicability of cell therapies.\nPreparing CMC documents requires integrating information from multiple departments, including manufacturing, quality assurance, clinical development, nonclinical research, and regulatory affairs. In addition to drafting and reviewing documents, considerable time and manpower are required to verify data consistency and identify errors or discrepancies across datasets.\nThrough the AI-powered platform, CHA Biotech plans to automate the drafting and review of CMC regulatory documents, improving document search, preparation, and review efficiency, enhancing regulatory compliance quality, strengthening global regulatory competitiveness, and shortening drug development and approval timelines.\nThe platform will also consolidate documents stored across multiple repositories and automate document preparation and review processes that have traditionally relied heavily on manual work.\nTo achieve this, the consortium will develop an integrated workflow covering search, analysis, content generation, and validation by leveraging a CMC-specialized large language model (LLM), four core validation agents -- including knowledge, template, and verification agents -- and AI operations (AIOps) technologies.\n\"We plan to build an automated system that structures dispersed document data and supports the entire regulatory documentation process, from drafting to validation,\" said Yoon Seok-hwan, executive director of CHA Biotech's AI team and principal investigator for the project. \"By demonstrating AI transformation in the highly demanding field of cell therapy CMC documentation, we aim to create a model case that accelerates AI adoption across the broader biotechnology industry.\"\nKim Young-gon, director of Persona AI's public business team, said, \"In high-precision domains such as CMC, agent-based AI combined with hyperautomation is essential because the process requires not only content generation but also rigorous validation. By integrating knowledge, template, and verification agents, we will enhance end-to-end automation for regulatory compliance and enable practical deployment in real-world operations.\"\nRelated articles\n- Matica Biotech, VaxDome partner to advance antiviral vaccine platform into clinic\n- CHA Biotech, Yonsei team up to support biohealth startups\n- CHA Biotech, Thermo Fisher Korea to build K-Bio CIC innovation hub in Pangyo\n- CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing\n- Matica Biolabs enters CAR-NK manufacturing with UCI Therapeutics CMO deal\n- CHA Biotech, Novartis Korea partner to launch K-Bio open innovation center\n- CHA Bio Group sells Solidus Investment stake to JW Holdings","reading_time_min":3,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 4164 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4164 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4164,"summary_length":365,"usable_text_length":4164,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4164,"summary_length":365}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4164 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4164,"summary_length":365,"usable_text_length":4164,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4164,"summary_length":365}},"actions":{"read":"/item/46891","export_markdown":"/api/items/46891/export?format=markdown","export_json":"/api/items/46891/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553"}},"digest":{"id":46891,"title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","source":"koreabiomed.com","topic":"ai","published_at":"2026-07-27T05:23:40+00:00","excerpt":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX)…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 4164 characters.","reading_time_min":3,"cluster_id":null},"card":{"display_title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","subtitle":"koreabiomed.com · 2026-07-27","summary":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the…","badges":["quality:high"],"links":{"read":"/item/46891","original":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","diagnose":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553"},"quality_warning":null},"export":{"title":"CHA Biotech wins $1.7 mil. government AI project for cell therapy documentation - koreabiomed.com","url":"https://www.koreabiomed.com/news/articleView.html?idxno=32553","summary":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI. The company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).","source":"koreabiomed.com","date":"2026-07-27T05:23:40+00:00","content":"CHA Biotech will automate the drafting and validation of regulatory documents required for cell therapy development and regulatory approval using generative AI.\nThe company said Monday that it has been selected for the Ministry of Science and ICT's \"AI Transformation (AX) One-Stop Voucher\" program, securing government funding worth 2.6 billion won ($1.7 million).\nThe AX One-Stop Voucher program is designed to accelerate AI adoption among Korean companies by providing integrated support in the form of vouchers for AI solutions, cloud services, and data utilization based on participating companies' digital transformation plans.\nCHA Biotech will establish a consortium with Naver Cloud, Persona AI, and MediPlus to develop a generative AI-based software-as-a-service (SaaS) platform supporting the commercialization of cell therapies.\nUnder the partnership, Naver Cloud will provide high-performance cloud infrastructure, Persona AI will develop AI solutions and build the SaaS platform, and MediPlus will be responsible for data structuring and quality validation.\nThe consortium aims to reduce delays in processing documents and data generated throughout the entire cell therapy lifecycle, from research and development to manufacturing.\nA key focus of the project is applying AI to the preparation of chemistry, manufacturing, and controls (CMC) regulatory documentation, which is essential for demonstrating the quality consistency, safety, reproducibility, and clinical applicability of cell therapies.\nPreparing CMC documents requires integrating information from multiple departments, including manufacturing, quality assurance, clinical development, nonclinical research, and regulatory affairs. In addition to drafting and reviewing documents, considerable time and manpower are required to verify data consistency and identify errors or discrepancies across datasets.\nThrough the AI-powered platform, CHA Biotech plans to automate the drafting and review of CMC regulatory documents, improving document search, preparation, and review efficiency, enhancing regulatory compliance quality, strengthening global regulatory competitiveness, and shortening drug development and approval timelines.\nThe platform will also consolidate documents stored across multiple repositories and automate document preparation and review processes that have traditionally relied heavily on manual work.\nTo achieve this, the consortium will develop an integrated workflow covering search, analysis, content generation, and validation by leveraging a CMC-specialized large language model (LLM), four core validation agents -- including knowledge, template, and verification agents -- and AI operations (AIOps) technologies.\n\"We plan to build an automated system that structures dispersed document data and supports the entire regulatory documentation process, from drafting to validation,\" said Yoon Seok-hwan, executive director of CHA Biotech's AI team and principal investigator for the project. \"By demonstrating AI transformation in the highly demanding field of cell therapy CMC documentation, we aim to create a model case that accelerates AI adoption across the broader biotechnology industry.\"\nKim Young-gon, director of Persona AI's public business team, said, \"In high-precision domains such as CMC, agent-based AI combined with hyperautomation is essential because the process requires not only content generation but also rigorous validation. By integrating knowledge, template, and verification agents, we will enhance end-to-end automation for regulatory compliance and enable practical deployment in real-world operations.\"\nRelated articles\n- Matica Biotech, VaxDome partner to advance antiviral vaccine platform into clinic\n- CHA Biotech, Yonsei team up to support biohealth startups\n- CHA Biotech, Thermo Fisher Korea to build K-Bio CIC innovation hub in Pangyo\n- CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing\n- Matica Biolabs enters CAR-NK manufacturing with UCI Therapeutics CMO deal\n- CHA Biotech, Novartis Korea partner to launch K-Bio open innovation center\n- CHA Bio Group sells Solidus Investment stake to JW Holdings","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.koreabiomed.com/news/articleView.html%3Fidxno%3D32553","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 4164 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 4164 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":4164,"summary_length":365,"usable_text_length":4164,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":4164,"summary_length":365}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}